LEO Pharma

News

Leo builds dermatology pipeline with Timber deal

Denmark's Leo Pharma has agreed to buy US medical dermatology company Timber Pharmaceuticals in a move that will expand its pipeline of therapies for rare skin diseases.

News

Chronic skin diseases - psoriasis, eczema, dermatitis.

Leo Pharma announces positive results for hand eczema study

In good news for patients living with chronic hand eczema (CHE), Leo Pharma – a company working to advance medical dermatology treatments – has unveiled positive topline results for i

News

LEO Pharma's Adtralza approved by MHRA, EC for adolescent at...

The Medicines and Healthcare products Regulatory Agency (MHRA) and the European Commission (EC) have

News

Leo puts target on Dupixent in US as FDA clears tralokinumab

Sanofi and Regeneron have another challenger to their big-selling drug Dupixent for atopic dermatitis, now that the FDA has approved Leo Pharma's rival antibody tralokinumab.

Views & Analysis